Correction to “Statin therapy and risk of Alzheimer's and age-related neurodegenerative diseases”

IF 4.9 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Pub Date : 2025-05-19 DOI:10.1002/trc2.70027

引用次数: 0

Abstract

Torrandell-Haro G, Branigan GL, Vitali F, Geifman N, Zissimopoulos JM, Brinton RD. Statin therapy and risk of Alzheimer's and age-related neurodegenerative diseases. Alzheimer's Dement. 2020; 6:e12108.

In Figure 2B, there was an error in the table where the values for risk reduction (RR) (95% confidence interval [CI]) of simvastatin for dementia and multiple Sclerosis (MS) were mistakenly duplicated. The correct value for simvastatin and risk of dementia is 0.59 (0.56–0.62), whereas the risk of MS was correctly presented as 0.45 (0.33–0.61). The correction in the table within Figure 2B does not change the statistical significance. Figure 2B has been updated to reflect the correct RR (95% CI) value for dementia associated with simvastatin and to address a publication-related adjustment to the X axis of Figure 2B. We sincerely apologize for the error in the RR value for dementia in the table within Figure 2B.

Abstract Image

查看原文本刊更多论文

更正“他汀类药物治疗与阿尔茨海默氏症和与年龄相关的神经退行性疾病的风险”

张晓明，张晓明，张晓明，等。他汀类药物治疗对老年痴呆和老年神经退行性疾病的影响。阿尔茨海默病。2020;6: e12108。在图2B中，表中有一个错误，辛伐他汀治疗痴呆和多发性硬化症（MS）的风险降低（RR）值（95%置信区间[CI]）被错误地重复了。辛伐他汀与痴呆风险的正确值为0.59(0.56-0.62)，而MS风险的正确值为0.45（0.33-0.61）。图2B中表格的修正并没有改变统计显著性。图2B已更新，以反映与辛伐他汀相关的痴呆的正确RR （95% CI）值，并解决与发表相关的图2B X轴调整。对于图2B中表格中痴呆的RR值有误，我们深表歉意。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Medicine-Psychiatry and Mental Health

CiteScore

10.10

自引率

2.10%

发文量

134

审稿时长

10 weeks

期刊介绍： Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.